Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia
| Autor: | Ernesta Audisio, Enrico Pogliani, Daniele Mattei, Vincenzo Cassibba, Elena Oldani, Claudio Romani, Monica Fumagalli, Alessandro Rambaldi, Filippo Marmont, Sergio Cortelazzo, Agostino Cortelezzi, Anna Maria Scattolin, Arianna Masciulli, Erika Borlenghi, Consuelo Corti, Manuela Tosi, Renato Bassan, Rosa Maria Marfisi, Andrea Gallamini, Giuseppe Rossi, Orietta Spinelli, Margherita Parolini, Tamara Intermesoli |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic medicine.medical_specialty Adolescent medicine.medical_treatment Pilot Projects Gastroenterology law.invention Young Adult Randomized controlled trial law Prednisone Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Injections Spinal Dexamethasone Aged Chemotherapy business.industry Cytarabine Neurotoxicity Articles Hematology Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Surgery Clinical trial Liposomes Female Methotrexate Post-Exposure Prophylaxis business medicine.drug |
| Zdroj: | Haematologica. 100:786-793 |
| ISSN: | 1592-8721 0390-6078 |
| DOI: | 10.3324/haematol.2014.123273 |
| Popis: | Developing optimal radiation-free central nervous system prophylaxis is a desirable goal in acute lymphoblastic leukemia, to avoid the long-term toxicity associated with cranial irradiation. In a randomized, phase II trial enrolling 145 adult patients, we compared intrathecal liposomal cytarabine (50 mg: 6/8 injections in B-/T-cell subsets, respectively) with intrathecal triple therapy (methotrexate/cytarabine/prednisone: 12 injections). Systemic therapy included methotrexate plus cytarabine or L-asparaginase courses, with methotrexate augmented to 2.5 and 5 g/m(2) in Philadelphia-negative B- and T-cell disease, respectively. The primary study objective was the comparative assessment of the risk/benefit ratio, combining the analysis of feasibility, toxicity and efficacy. In the liposomal cytarabine arm 17/71 patients (24%) developed grade 3-4 neurotoxicity compared to 2/74 (3%) in the triple therapy arm (P=0.0002), the median number of episodes of neurotoxicity of any grade was one per patient compared to zero, respectively (P=0.0001), and even though no permanent disabilities or deaths were registered, four patients (6%) discontinued intrathecal prophylaxis on account of these toxic side effects (P=0.06). Neurotoxicity worsened with liposomal cytarabine every 14 days (T-cell disease), and was improved by the adjunct of intrathecal dexamethasone. Two patients in the liposomal cytarabine arm suffered from a meningeal relapse (none with T-cell disease, only one after high-dose chemotherapy) compared to four in the triple therapy arm (1 with T-cell disease). While intrathecal liposomal cytarabine could contribute to improved, radiation-free central nervous system prophylaxis, the toxicity reported in this trial does not support its use at 50 mg and prompts the investigation of a lower dosage. (clinicaltrials.gov identifier: NCT-00795756). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|